Alzamend Neuro Regains Compliance with Nasdaq Listing Standards

Nasdaq confirms Alzamend meets the equity requirement, easing delisting risk and allowing management to refocus on AL001 Phase II trials.

Rhea-AI Summary

Alzamend Neuro (ALZN) has regained compliance with Nasdaq Listing Rule 5550(b)(1) on stockholders' equity, following a Nasdaq notice dated September 14, 2026.

To meet the rule, the company needed minimum stockholders' equity of $2.5 million and reported equity of $5,802,680 in its Form 10-Q for the quarter ended July 31, 2026, filed on September 10, 2026. Nasdaq confirmed that Alzamend now complies with the Equity Rule and that the matter is closed. Earlier, on March 20, 2026, Nasdaq had notified Alzamend that it did not meet certain continued listing standards and set a deadline, later extended to September 16, 2026, to regain compliance. The CEO said the company will now focus on advancing AL001 through four Phase II clinical trials with Massachusetts General Hospital, including completed work in a healthy cohort and an ongoing bipolar disorder cohort.

Positive

• Stockholders' equity $5,802,680 vs. $2.5 million Nasdaq minimum as of July 31, 2026
• Nasdaq compliance regained under Listing Rule 5550(b)(1); prior deficiency matter closed

Negative

• None.

Market Context

On Aug 4, 2026, Alzamend's $7.5 million initial Series D tranche was followed by an 8.21% 24-hour ga...

Analysis

On Aug 4, 2026, Alzamend's $7.5 million initial Series D tranche was followed by an 8.21% 24-hour gain; that financing preceded the equity level cited in the Nasdaq compliance notice.

Key Figures

Minimum stockholders' equity: $2.5 million Stockholders' equity: $5,802,680 Compliance notice date: September 14, 2026 +1 more

Minimum stockholders' equity

$2.5 million

Nasdaq Listing Rule 5550(b)(1) requirement

Stockholders' equity

$5,802,680

Quarter ended July 31, 2026

Compliance notice date

September 14, 2026

Nasdaq notification of regained compliance

Compliance deadline

September 16, 2026

Deadline granted by Nasdaq

Historical Context

1 past event · Latest: Aug 04

1 event

1. Aug 04

   Series D financing

   24h Move

   +8.2%

   Initial $7.5 million tranche increased equity ahead of Nasdaq compliance resolution

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

form 10-q, stockholders' equity, phase ii clinical trials

3 terms

form 10-q regulatory

"Quarterly Report on Form 10-Q for the quarter ended July 31, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

stockholders' equity financial

"Alzamend needed to have a minimum stockholders' equity of $2.5 million"

Stockholders' equity is the portion of a company's assets that belongs to its owners after all debts and obligations are paid; think of it as the value left for shareholders if the company sold everything and paid off what it owes. Investors watch it because it shows the company's net worth, indicates how much of growth is funded by owners versus debt, and helps assess financial health and the potential for future dividends or stock value increases — like the equity in a house after the mortgage is settled.

phase ii clinical trials medical

"advancing AL001 through four Phase II clinical trials"

Phase II clinical trials are studies that evaluate whether an experimental drug or therapy actually works and is reasonably safe in a larger group of patients after initial safety checks. Investors care because results provide the first meaningful evidence of effectiveness and side effects—like a prototype tested with real users—informing whether a program is likely to advance, shaping a drug’s future value and the company’s funding and partnership prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ATLANTA, Sept. 16, 2026 /PRNewswire/ -- Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that it has received a notification letter (the "Compliance Notice") from the Listing Qualifications Staff of the Nasdaq Stock Market, LLC ("Nasdaq") dated September 14, 2026, informing Alzamend that it has regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Rule"). In order to regain compliance with the Equity Rule, Alzamend needed to have a minimum stockholders' equity of $2.5 million. Based on Alzamend's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, which was dated and filed with the U.S. Securities and Exchange Commission on September 10, 2026, Alzamend evidenced stockholders' equity of $5,802,680. Accordingly, in the Compliance Notice, Nasdaq stated that Alzamend complies with the Equity Rule and the matter is now closed.

As previously reported, on March 20, 2026, Alzamend was notified by Nasdaq that it did not meet the minimum market value of listed securities requirement for continued listing on Nasdaq under Nasdaq Listing Rule 5550(b)(1), or any other continued listing standard, such as the Equity Rule, and was provided 45 calendar days, or until May 4, 2026, to submit a plan to regain compliance. Alzamend submitted its plan to Nasdaq to regain compliance with the Equity Rule, which was accepted by Nasdaq and Alzamend was granted until September 16, 2026 to regain compliance.

Stephan Jackman, CEO of Alzamend, stated, "We are very pleased to have regained compliance with Nasdaq's continued listing standards. Maintaining our Nasdaq listing is fundamental to Alzamend's mission, and we are grateful for our investors' support. With this behind us, our full focus returns to advancing AL001 through four Phase II clinical trials in partnership with Massachusetts General Hospital. We have made significant progress: the healthy human cohort initiated in May 2025 completed its clinical portion in November 2025, and we reported topline data in March 2026. Building on that momentum, we initiated the BD cohort in April 2026 and look forward to completing that trial while sequentially initiating the three remaining cohorts in patients with Alzheimer's, MDD and PTSD."

About Alzamend Neuro

Alzamend is a clinical-stage biopharmaceutical company developing novel therapies for Alzheimer's, BD, MDD and PTSD. Our mission is to rapidly develop and market safe and effective treatments. Our current pipeline consists of two novel therapeutic drug candidates, AL001, a patented ionic cocrystal delivering lithium with salicylate and L-proline designed to improve brain delivery and safety compared to conventional lithium, and ALZN002, a patented cell-based therapeutic vaccine designed to restore the immune system's ability to clear Alzheimer's beta-amyloid. The latter is a next-generation active-immunity approach offering potential advantages in dosing frequency and cost compared to approved passive-immunity antibody therapies. Both candidates are exclusively licensed from the University of South Florida Research Foundation under royalty-bearing worldwide licenses.

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as "believes," "plans," "anticipates," "projects," "estimates," "expects," "intends," "strategy," "future," "opportunity," "may," "will," "should," "could," "potential," or similar expressions that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties. Forward-looking statements speak only as of the date they are made, and Alzamend undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect Alzamend's business and financial results are included in Alzamend's filings with the U.S. Securities and Exchange Commission. All filings are available at www.sec.gov and on Alzamend's website at www.Alzamend.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/alzamend-neuro-regains-compliance-with-nasdaq-listing-standards-302880453.html

SOURCE Alzamend Neuro, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What specific Nasdaq rule did Alzamend Neuro need to satisfy to regain compliance?

Alzamend needed to comply with Nasdaq Listing Rule 5550(b)(1), referred to as the Equity Rule, which requires a minimum level of stockholders' equity for continued listing on the Nasdaq Capital Market.

How did Alzamend Neuro demonstrate compliance with the Nasdaq equity requirement?

Compliance was demonstrated through Alzamend's Quarterly Report on Form 10-Q for the quarter ended July 31, 2026, filed on September 10, 2026, which reported stockholders' equity of $5,802,680, above the required $2.5 million.

What was the timeline of Nasdaq's deficiency and compliance process for Alzamend?

On March 20, 2026, Nasdaq notified Alzamend that it did not meet certain continued listing standards and gave 45 days, until May 4, 2026, to submit a compliance plan. After Alzamend submitted its plan, Nasdaq accepted it and granted an extension until September 16, 2026 to regain compliance. Nasdaq then issued the Compliance Notice dated September 14, 2026, confirming compliance and closing the matter.

What is the current status of Alzamend's AL001 clinical development program?

The company stated that AL001 is being advanced through four Phase II clinical trials in partnership with Massachusetts General Hospital. A healthy human cohort initiated in May 2025 completed its clinical portion in November 2025, with topline data reported in March 2026. A bipolar disorder (BD) cohort was initiated in April 2026, and Alzamend plans to complete that trial while sequentially initiating three additional cohorts in patients with Alzheimer's, major depressive disorder (MDD) and post-traumatic stress disorder (PTSD).